Gentamicin implant - Innocoll

Drug Profile

Gentamicin implant - Innocoll

Alternative Names: Cogenzia; CollaRx; CollaRx® gentamicin topical - Innocoll; Collatamp EG; Collatamp G; Collatamp G topical; Cronocol; Duracoll; Garacol; Garacoll; Garamycin Schwamm; Gentacol; Gentacoll; Gentalyn; Gentamicin surgical implant - Innocoll; Gentamicin-collagen Topical; Gentimplant; INL-002; Sulmycin Implant; Sulmycin Implant E; Sulmycin Schwamm

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Essex Chemie; Innocoll
  • Developer Innocoll; Premier Research Group
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Postoperative infections
  • Phase III Diabetic foot ulcer

Most Recent Events

  • 24 Jul 2017 Innocoll has been acquired by Gurnet point capital
  • 03 Nov 2016 Topline efficacy and adverse events data from the phase III COACT-1 and COACT-2 studies in Diabetic foot ulcer (Combination therapy, In adults, In the elderly) released by Innocoll
  • 23 Jun 2016 Innocoll Holdings completes enrolment in the phase III COACT-1 trial for Diabetic foot ulcer in USA (NCT02427802)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top